These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26578722)

  • 1. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).
    Yoon HH; Foster NR; Meyers JP; Steen PD; Visscher DW; Pillai R; Prow DM; Reynolds CM; Marchello BT; Mowat RB; Mattar BI; Erlichman C; Goetz MP
    Ann Oncol; 2016 Feb; 27(2):339-44. PubMed ID: 26578722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
    Hayashi H; Kurata T; Takiguchi Y; Arai M; Takeda K; Akiyoshi K; Matsumoto K; Onoe T; Mukai H; Matsubara N; Minami H; Toyoda M; Onozawa Y; Ono A; Fujita Y; Sakai K; Koh Y; Takeuchi A; Ohashi Y; Nishio K; Nakagawa K
    J Clin Oncol; 2019 Mar; 37(7):570-579. PubMed ID: 30653423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP.
    Folprecht G; Trautmann K; Stein A; Huebner G; Stahl M; Kasper S; Kretzschmar A; Köhne CH; Grünwald V; Hofheinz RD; Schütte K; Löffler H; Bokemeyer C; Krämer A;
    Br J Cancer; 2021 Feb; 124(4):721-727. PubMed ID: 33235314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
    Pentheroudakis G; Briasoulis E; Kalofonos HP; Fountzilas G; Economopoulos T; Samelis G; Koutras A; Karina M; Xiros N; Samantas E; Bamias A; Pavlidis N;
    Acta Oncol; 2008; 47(6):1148-55. PubMed ID: 18607872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
    Hainsworth JD; Daugaard G; Lesimple T; Hübner G; Greco FA; Stahl MJ; Büschenfelde CM; Allouache D; Penel N; Knoblauch P; Fizazi KS
    Cancer; 2015 May; 121(10):1654-61. PubMed ID: 25611313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.
    McWilliams RR; Allred JB; Slostad JA; Katipamula R; Dronca RS; Rumilla KM; Erickson LA; Bryce AH; Joseph RW; Kottschade LA; King DM; Leitch JM; Markovic SN
    Cancer; 2018 Feb; 124(3):537-545. PubMed ID: 29044496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
    Eberhardt WE; Mitchell P; Schiller JH; Brown MP; Thomas M; Mills G; Jehl V; Urva SR; De Leo JJ; Gogov S; Papadimitrakopoulou V
    Invest New Drugs; 2014 Feb; 32(1):123-34. PubMed ID: 23579358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
    Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J; Kono SA; Lewis C; Chen AY; Higgins K; El-Deiry M; Wadsworth T; Beitler JJ; Shin DM; Sun SY; Khuri FR
    Cancer; 2014 Dec; 120(24):3940-51. PubMed ID: 25103371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.
    Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D
    Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
    Maemondo M; Inoue A; Sugawara S; Harada T; Minegishi Y; Usui K; Miwa K; Morikawa N; Kambe M; Ube K; Watanabe K; Ishimoto O; Sakakibara T; Gemma A; Nukiwa T
    Oncologist; 2014 Apr; 19(4):352-3. PubMed ID: 24682465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.
    Wheatley-Price P; Gadgeel S; Takahashi T; Li X; Dar M; Blumenschein GR
    Clin Lung Cancer; 2019 May; 20(3):e362-e368. PubMed ID: 30685114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
    Hainsworth JD; Spigel DR; Thompson DS; Murphy PB; Lane CM; Waterhouse DM; Naot Y; Greco FA
    Oncologist; 2009 Dec; 14(12):1189-97. PubMed ID: 19965914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.
    Gonzalez-Angulo AM; Akcakanat A; Liu S; Green MC; Murray JL; Chen H; Palla SL; Koenig KB; Brewster AM; Valero V; Ibrahim NK; Moulder-Thompson S; Litton JK; Tarco E; Moore J; Flores P; Crawford D; Dryden MJ; Symmans WF; Sahin A; Giordano SH; Pusztai L; Do KA; Mills GB; Hortobagyi GN; Meric-Bernstam F
    Ann Oncol; 2014 Jun; 25(6):1122-7. PubMed ID: 24669015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
    Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
    Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
    J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
    Socinski MA; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Yamamoto N; Zhang H; Renschler MF
    Ann Oncol; 2013 Sep; 24(9):2390-6. PubMed ID: 23842283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.
    Saba NF; Force S; Staley C; Fernandez F; Willingham F; Pickens A; Cardona K; Chen Z; Goff L; Cardin D; Lambright E; Nesbitt J; Krasinskas A; Higgins K; Harvey RD; Owonikoko T; Ramalingam SS; Shin DM; Beitler JJ; El-Rayes BF; Salaria S; El-Rifai W; Landry J; Chakravarthy AB
    Am J Clin Oncol; 2019 Apr; 42(4):331-336. PubMed ID: 30789414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
    van der Burg ME; Vergote I; Onstenk W; Boere IA; Leunen K; van Montfort CA; van Doorn HC
    Eur J Cancer; 2013 Apr; 49(6):1254-63. PubMed ID: 23276720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.